CCM
BMY icon

Cullen Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Cullen Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.2M Buy
1,132,367
+12,698
+1% +$729K 0.64% 51
2026
Q1 		$67.9M Sell
1,119,669
-57,057
-5% -$3.33M 0.7% 47
2025
Q4 		$63.5M Sell
1,176,726
-164,121
-12% -$7.9M 0.69% 43
2025
Q3 		$60.5M Buy
1,340,847
+79,777
+6% +$3.73M 0.66% 48
2025
Q2 		$58.4M Buy
1,261,070
+142,481
+13% +$6.99M 0.66% 46
2025
Q1 		$68.2M Sell
1,118,589
-47,588
-4% -$2.77M 0.79% 44
2024
Q4 		$66M Sell
1,166,177
-144,826
-11% -$8.09M 0.77% 42
2024
Q3 		$67.8M Sell
1,311,003
-175,866
-12% -$8.25M 0.74% 42
2024
Q2 		$61.7M Buy
1,486,869
+220,358
+17% +$9.86M 0.71% 44
2024
Q1 		$68.7M Buy
1,266,511
+134,460
+12% +$6.85M 0.76% 44
2023
Q4 		$58.1M Buy
1,132,051
+80,760
+8% +$4.24M 0.86% 44
2023
Q3 		$61M Buy
1,051,291
+1,785
+0.2% +$109K 0.71% 44
2023
Q2 		$67.1M Buy
1,049,506
+105,310
+11% +$7.06M 0.6% 45
2023
Q1 		$65.4M Buy
944,196
+292,065
+45% +$20.6M 0.6% 44
2022
Q4 		$46.9M Sell
652,131
-168,213
-21% -$12.7M 0.6% 52
2022
Q3 		$58.3M Buy
820,344
+48,133
+6% +$3.49M 0.62% 45
2022
Q2 		$59.5M Buy
772,211
+93,820
+14% +$7.15M 0.6% 49
2022
Q1 		$49.5M Buy
678,391
+64,311
+10% +$4.32M 0.46% 57
2021
Q4 		$38.3M Buy
614,080
+64,717
+12% +$3.8M 0.36% 68
2021
Q3 		$32.5M Buy
549,363
+28,034
+5% +$1.85M 0.32% 71
2021
Q2 		$34.8M Buy
521,329
+38,306
+8% +$2.5M 0.34% 73
2021
Q1 		$30.5M Buy
483,023
+396,688
+459% +$24.7M 0.33% 74
2020
Q4 		$5.36M Buy
86,335
+71,915
+499% +$4.42M 0.3% 56
2020
Q3 		$869K Hold
14,420
– – 0.05% 97
2020
Q2 		$848K Sell
14,420
-3,815
-21% -$228K 0.05% 99
2020
Q1 		$1.02M Hold
18,235
– – 0.06% 91
2019
Q4 		$1.17M Sell
18,235
-6,095
-25% -$349K 0.05% 89
2019
Q3 		$1.23M Buy
+24,330
New +$1.14M 0.05% 89

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cullen Capital Management's BMY Position: Q2 2026 in Review

Cullen Capital Management increased its Bristol-Myers Squibb (BMY) stake by 1.1% in Q2 2026, buying an estimated $729K and bringing the position to 1,132,367 shares worth $65.2M. The position accounts for 0.64% of the portfolio, ranked #51.

Cullen Capital Management first reported a position in BMY in Q3 2019 and has held it in 28 quarters since. The position peaked at $68.7M in Q1 2024. 2,514 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Cullen Capital Management held 1,132,367 shares of Bristol-Myers Squibb worth $65.2M as of Q2 2026.
  • Cullen Capital Management bought 12,698 Bristol-Myers Squibb shares in Q2 2026, an estimated $729K.
  • Bristol-Myers Squibb made up 0.64% of Cullen Capital Management's portfolio in Q2 2026, its #51 holding.
  • Cullen Capital Management first reported a position in Bristol-Myers Squibb in Q3 2019 and has held it in 28 quarters since.
  • Cullen Capital Management's Bristol-Myers Squibb position peaked at $68.7M in Q1 2024.
  • 2,514 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Cullen Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.